ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1157

Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Abstract Number: 0019

Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
Abstract Number: 1627

BAFF-var Is a New Predisposing Factor for Primary Sjögren’s Syndrome (pSS) and Impacts Disease Activity
Abstract Number: 1713

Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
Abstract Number: 0046

Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion
Abstract Number: 1995

Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
Abstract Number: 2210

Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
Abstract Number: 0585

Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
Abstract Number: 2133

Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
Abstract Number: 1911

Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning
Abstract Number: 0125

Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab
Abstract Number: 1457

Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
Abstract Number: 0276

Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
Abstract Number: 0864

Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Abstract Number: 0460

Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].